CRISPR Therapeutics to Present at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View from the Top Conference
ZUG, Switzerland and CAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics, is scheduled to present at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View from the Top conference on Thursday, January 9, 2020, at 1:10 p.m. ET.
A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer AG, Vertex Pharmaceuticals and ViaCyte, Inc.CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in London, United Kingdom. For more information, please visit www.crisprtx.com.
WCG on behalf of CRISPR
Source: CRISPR Therapeutics AG
You are now leaving the CRISPR Therapeutics website.
CRISPR Therapeutics is not responsible for the content or availability of third-party sites.